Skip to Content
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site
Last Updated: 04/13/22

Current Funding Opportunities

The Requests for Applications (RFAs) and Program Announcements (PAs) listed below communicate CDP’s current funding opportunities and research interests. CDP staff contacts and published notices are provided in the summary link for each opportunity. We encourage you to discuss your proposed research with a CDP program director before you submit an application. This page updates to reflect the active Funding Opportunities.

To receive email updates, click here or follow us on Twitter.

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed): PAR-22-049

Reissue of PAR-18-947
Posted date: October 22, 2021
Expiration date: September 14, 2024
Application Receipt Dates: January 11, 2022; June 07, 2022; September 13, 2022; January 11, 2023; June 07, 2023; September 13, 2023; January 11, 2024; June 07, 2024; September 13, 2024 by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as "liquid biopsies", or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

See full announcement here.

Contact: Dr. Lokesh Agrawal, lokesh.agrawal@nih.gov or Dr. Abhi Rao abhi.rao@nih.gov

National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required): PAR-21-033

Reissue of PAR-18-560
Posted date: November 10, 2020
Expiration date: January 8, 2024
Application Receipt Dates: Standard application dates apply for non-AIDS applications; standard AIDS dates apply for AIDS applications.

The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.

See full announcement here.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional): PAR-20-292

Reissue of PAR-19-356
Posted date: August 24, 2020
Expiration date: July 21, 2022
Application Receipt Dates: Standard application dates apply for non-AIDS applications; standard AIDS dates apply for AIDS applications.

This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well.

This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed.

See full announcement here.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Assay Validation of High-Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed): PAR-20-313

Reissue of PAR-18-317. Posted date: October 13, 2020;
Expiration date: October 11, 2023.
Application receipt dates: February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

See full announcement here.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Assay Validation for High Quality Markers for Clinical Studies in Cancer (UH3) (Clinical Trials Not Allowed): PAR-20-314

Reissue of PAR-18-310, Posted date: October 13, 2020;
Expiration Date: October 11, 2023
Application receipt dates: February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

See full announcement here.

Contact Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed): PAR-20-074.

Reissue of PAR-17-003; Posted date: December 10, 2019.
Expiration Date: October 29, 2022.
Application Due dates: February 28, 2020; July 10, 2020; October 27, 2020; February 26, 2021; July 13, 2021; October 26, 2021; February 28, 2022; July 11, 2022; October 28, 2022, by 5 pm local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

See full announcement here.

Contact Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Bioengineering Technologies

The NIH bioengineering program supports basic, applied, and translational bioengineering research that addresses important biological or medical research problems.

CDP contact: Dr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Exploratory/Developmental Bioengineering Research Grants [EBRG]: PAR-22-090 and PAR-22-091 (R21)

Reissue of PAR-19-149 and PAR-19-150
Release/Posted Date: January 11, 2022
Expiration date: January 8, 2025
Application Receipt Dates: Standard due dates apply.

The EBRGs support early bioengineering research. EBRG applications may contain minimal or no preliminary data, and may propose hypothesis-driven, discovery-driven or design-directed research.

See full announcements here and here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Bioengineering Research Grants [BRG]: PAR-19-158 and PAR-19-159 (R01)

Reissue of PAR-18-206
Posted Date: January 8, 2019;
Expiration date: May 8, 2022 — will be reissued
Application Receipt Dates: Standard receipt dates for non-AIDS applications; standard AIDS dates for AIDS applications.

The purpose of this FOA is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach.

See full announcements here and here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Bioengineering Partnership with Industry [BPI] (U01)

Release/Posted Date: March 08, 2022
Expiration date: January 8, 2025
Application Receipt Dates: May 26, 2022; September 26, 2022; May 26, 2023; September 26, 2023; May 24, 2024; September 26, 2024

The purpose of the BPI FOA will be to encourage applications to: 1) establish a robust engineering solution to a problem in biomedical research or the practice of medicine; 2) develop a strategic alliance of multi-disciplinary partners based on a well-defined leadership plan; and 3) realize a specific endpoint within 5-10 years based on a detailed plan with a timeline and quantitative milestones.

See announcement here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01): PAR-21-166 (Clinical Trial Not Allowed) and PAR-21-206 (Clinical Trial Optional)

PAR-21-166 is a re-issue of PAR-18-530
Posted date: March 25, 2021
Expiration dates: May 08, 2024 (PAR-21-166) and January 08, 2024 (PAR-21-206)
Application receipt dates: Standard due dates apply.

These FOAs specify a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status.

See full announcements here and here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional): PAR-22-099

Re-issue of PAR-19-113
Posted date: January 21, 2022
Expiration date: May 08, 2025
Application receipt dates: Standard due dates apply.

This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.

See full announcement here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01) RFA-HG-21-001

Posted date: July 9, 2021
Expiration date: June 16, 2023
Application receipt dates: October 1, 2021; June 15, 2022; June 15, 2023.

This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.

See full announcement here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Innovative Molecular Analysis Technologies (IMAT) Program

The Innovative Molecular Analysis Technologies (IMAT) program was established to support the development, technical maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation. In support of its mission, the IMAT program utilizes a variety of investigator-initiated research project grant mechanisms while retaining a strong commitment to diversity and to the training of scientists and clinicians in cross-cutting, research-enabling disciplines.

Mechanism Theme Molecular/Cellular Analysis Cancer-relevant Biospecimen Science
R61 Exploratory-pilota RFA-CA-22-001 RFA-CA-22-003
R33 Advanced Developmentb RFA-CA-22-002 RFA-CA-22-004
R01
U01
U54
P01
P50
U2C
Integration & Validation RFA-CA-22-005
RFA-CA-22-006
RFA-CA-22-007
RFA-CA-22-008
RFA-CA-22-009
RFA-CA-22-010

a While no preliminary data are necessary, the applicants must demonstrate the innovative nature of the particular technology and/or approach proposed for development.

b Detailed preliminary data must be provided in support of the feasibility of the technology or approach that is proposed for development. Such data may reflect successful completion of a previous R21 grant and associated performance measures.

Expiration date for the listed IMAT FOAs is September 23, 2022.

CDP contacts: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov; Dr. Brian Sorg, 240-276-5712, brian.sorg@mail.nih.gov; Dr. Tawnya McKee, 240-276-5719, mckeeta@mail.nih.gov

Small Business Innovation Research Funding Opportunities

NIH/NCI 438 - Understanding Cancer Tumor Genomic Results: Technology Applications for Community Providers

Receipt date: October 28, 2021 5:00 PM Eastern Daylight Time

The goal is to design and develop products such as tools, technologies, and/or services to: (i) inform oncology providers about tumor/somatic testing and current NCCN guidelines, (ii) help oncology providers evaluate the need for tumor/somatic testing for specific cancer patients, (iii) assist oncology providers with interpretation of tumor/somatic test results, including the impact of incidental germline findings, and (iv) help oncology providers communicate NGS results to their patients. Interpretation of NGS results must be personalized for individual patients. Products that cater to settings with limited or no access to genetic counselors, or on-site tumor boards, are encouraged. Products should: (i) identify strategies for enhancing provider understanding of cancer genomic test results; (ii) assist with provider communication of test results in a clear and lay-friendly manner, to aid both treatment and life planning decisions; (iii) inform providers about genetic counseling and clinical trial resources for their patients; (iv) offer remote technology applications such as video and telephone guidance; and (v) incorporate perspectives of populations experiencing disparities in cancer outcomes, such as minority and rural communities. In addition, contractors must evaluate, pilot and disseminate the product. For more information, click here.

Contact: Cherie Wells (ncioasbir@mail.nih.gov)

NIH/NCI 445 - Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-based Therapies

Receipt date: October 28, 2021, 5:00 p.m. Eastern Daylight Time

The overall goal of this solicitation is to stimulate the development of advanced manufacturing technologies that substantially improve the speed and cost of producing autologous cell-based therapies. Technical solutions are expected to address a key bottleneck in the current manufacturing process for individual cell-based therapies. Ideal solutions will involve parallel processing, rapid release testing, or point of care technology development, although other approaches may also be considered responsive. New technologies must produce cell-based products of equal or superior quality as compared to current manufacturing methods. The development of scalable systems capable of changing the number of cell products produced simultaneously, is strongly encouraged. For example, technologies may involve a modular engineering approach in which the system can be readily adapted as the demand for autologous cell therapies changes.

To achieve the goals of the solicitation, offerors must be improving upon an existing end to end process that they have experience with, rather than developing end to end processes as part of the project. To be responsive, proposals must involve a collaboration between technology developers and clinical researchers with experience developing and treating patients with autologous cell-based cancer therapies. Projects also including an immunologist on the team will be prioritized. Phase I projects will be expected to involve feasibility testing of the proposed advanced manufacturing technology. A key activity during the Phase I project is to benchmark the novel advanced manufacturing approach against the current manufacturing method for a specific autologous cell-based product. More specifically, the research plan must include validating the proposed novel manufacturing approach against a process that has been used to produce product for clinical trials by demonstrating comparability of products with respect to specific critical quality attributes. Phase II projects will be expected to conduct full-scale processing to demonstrate a substantial increase in the speed and cost of producing autologous cell-based therapies. It is anticipated that most offerors will propose to study T-cell-based immunotherapy products, although other cell types are also encouraged (e.g., NK cells). Advanced manufacturing approaches may involve genetic engineering and optimization as appropriate for the cell-based therapy product, but the primary goal is to achieve substantial cost and throughput improvements for the overall vein-to-vein process. For more information, click here.

Cherie Wells (ncioasbir@mail.nih.gov)

NIH/NCI 439 - Advanced Sample Processing Platforms for Downstream Single-cell Multi-omic Analysis

Receipt date: October 28, 2021, 5:00 p.m. Eastern Daylight Time

The offerors are encouraged to integrate the preanalytical workflow from tumor cell dissociation/isolation, enrichment, tracking, cell lysis, to biomolecular isolation on a single platform to enable single cell multimodal-omic analysis. This approach should provide smoother transitions between functional components thereby leading to shorter analysis time and thus higher throughput. In addition, by omitting human intervention, workflow with higher degree of automation should ultimately translate into greater experimental reproducibility. Novel micropillar-based microfluidic platforms that are capable of providing high efficiency separation, isolation and enrichment of single cells and molecules instead of relying on a single-compartment design (e.g. droplet microfluidics, microwell technologies, valved and chambered microchannels, tube-based kits, etc.) for cell and biomolecular processing may be explored. Micropillar arrays within microfluidic channels may serve to physically size-separate genomic DNA from proteins and RNA during cell lysis in a manner compatible with the downstream target analysis.

Overall, at the end of the contract an offeror is expected to provide a robust sample processing platform that easily integrates with scMulti-omic analysis and allow better understanding of heterogeneity in solid tumors and the microenvironment, and also that enable analysis of rare and low-abundant cells such as circulating tumor cells and antigen presenting cells, to potentially open the door to new biomarker and therapeutic targets discoveries in cancer.

The activities that fall within the scope of this solicitation include development of technologies to improve single-cell multi-omic preanalytical microfluidic platforms that integrate steps of the preanalytical workflow such as sample processing, single-cell separation or isolation and enrichment, technologies for solid tumor dissociation/isolation, enrichment and tracking of cancer cells and/or biomolecules for scMulti-omics. Technology proposals focused on developing new or improved molecular analysis will be considered non-responsive to this contract topic. For more information, click here.

Contact: Cherie Wells (ncioasbir@mail.nih.gov)

Informatics Technology for Cancer Research (ITCR) Program (http://itcr.nci.nih.gov/)

ITCR supports a wide range of informatics tools to serve current and emerging needs across the cancer research continuum. ITCR has issued four Funding Opportunity Announcements aimed at successive stages of informatics technology development: Algorithm Development (R21), Prototyping and Hardening (U01), Enhancement and Dissemination (U24), Sustainment (U24). Click here to find the current FOAs for each category.

FOR THE LATEST INFORMATION ABOUT NCI INITIATIVES, VISIT
Division of Extramural Activities, National Cancer Institute
http://deainfo.nci.nih.gov/funding.htm

National Institutes of Health
U.S. Department of Health and Human Services